China Universal Asset Management Company’s Allogene Therapeutics ALLO Stock Holding History
Bought
Maintained
Sold
Other funds holding ALLO
WCM
HWAM
HDA
PFSRSONJ
CWMS
BCM
WP
AHL
IHL
China Universal Asset Management Company's ALLO Position: Q2 2026 in Review
China Universal Asset Management Company increased its Allogene Therapeutics (ALLO) stake by 38% in Q2 2026, buying an estimated $33.1K and bringing the position to 54,931 shares worth $114K. The position accounts for 0.01% of the portfolio, ranked #404.
China Universal Asset Management Company first reported a position in ALLO in Q3 2022 and has held it in 16 quarters since. The position peaked at $145K in Q1 2024. 26 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.
- China Universal Asset Management Company held 54,931 shares of Allogene Therapeutics worth $114K as of Q2 2026.
- China Universal Asset Management Company bought 15,051 Allogene Therapeutics shares in Q2 2026, an estimated $33.1K.
- Allogene Therapeutics made up 0.01% of China Universal Asset Management Company's portfolio in Q2 2026, its #404 holding.
- China Universal Asset Management Company first reported a position in Allogene Therapeutics in Q3 2022 and has held it in 16 quarters since.
- China Universal Asset Management Company's Allogene Therapeutics position peaked at $145K in Q1 2024.
- 26 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.
Based on China Universal Asset Management Company's 13F filing for Q2 2026, filed 24 Jul 2026.